



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

12-6-214/A-1, Hyderabad Road,
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91 - 8532 - 238876

E-Mail : info@vbshilpa.com Web: <http://www.vbshilpa.com>

CIN No. L85110KA1987PLC008739

SML/184/2016-17

13th December, 2016

To
Corporate Relationship Department
BSE Limited,
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
MUMBAI - 400 001.

To
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI - 400 051.

Dear Sir,

Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015.

Ref: Stock Code: NSE: SHILPAMED/BSE - 530549

With reference to the above subject, we hereby intimate you that SHILPA MEDICARE LIMITED has received an approval from the United States Food & Drug Administration (USFDA) (the Office of Bioequivalence) for Capecitabine Tablets USP, 150 mg and 500 mg to be bioequivalent and therapeutically equivalent to the reference listed drug product (RLD), Xeloda Tablets, 150 mg and 500 mg of Hoffmann-La Roche, Inc.

This is for your information and doing the needful.

Thanking you,

Yours faithfully,
For SHILPA MEDICARE LIMITED


VISHNUKANT BHUTADA
MANAGING DIRECTOR

